Drug Trial Radar · NCT05633602
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
838
Actual
Start
Mar 14, 2023
Primary completion
Nov 26, 2025
Study completion Mar 15, 2028
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); Eli Lilly and Company; Merck Sharp & Dohme LLC
- First posted
- Dec 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Conditions
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
Interventions
ChemotherapyDrug
Receive standard of care chemotherapy
PembrolizumabBiological
Given IV
RamucirumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survivalTime frame: From date of randomization to date of death due to any cause, assessed up to 3 years
Locations
566 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
Highlands Oncology Group - Fayetteville
Fayetteville, Arkansas
Mercy Hospital Fort Smith
Fort Smith, Arkansas
John L McClellan Memorial Veterans Hospital
Little Rock, Arkansas
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Highlands Oncology Group - Rogers
Rogers, Arkansas
Highlands Oncology Group
Springdale, Arkansas
Kaiser Permanente-Anaheim
Anaheim, California
PCR Oncology
Arroyo Grande, California
Sutter Auburn Faith Hospital
Auburn, California
Kaiser Permanente-Baldwin Park
Baldwin Park, California
Kaiser Permanente-Bellflower
Bellflower, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Tower Cancer Research Foundation
Beverly Hills, California
Marshall Cancer Center
Cameron Park, California
City of Hope Comprehensive Cancer Center
Duarte, California
Kaiser Permanente Dublin
Dublin, California
Kaiser Permanente-Fontana
Fontana, California
Kaiser Permanente-Fremont
Fremont, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Kaiser Permanente - Harbor City
Harbor City, California
City of Hope at Huntington Beach
Huntington Beach, California
City of Hope at Irvine Lennar
Irvine, California
Kaiser Permanente-Irvine
Irvine, California
City of Hope Antelope Valley
Lancaster, California
Loma Linda University Medical Center
Loma Linda, California
City of Hope at Long Beach Elm
Long Beach, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Kaiser Permanente West Los Angeles
Los Angeles, California
Cedars Sinai Medical Center
Los Angeles, California
Fremont - Rideout Cancer Center
Marysville, California
Memorial Medical Center
Modesto, California
Kaiser Permanente-Modesto
Modesto, California
City of Hope Newport Beach
Newport Beach, California
Kaiser Permanente-Oakland
Oakland, California
Kaiser Permanente-Ontario
Ontario, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Showing 40 of 566 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.